a public good project by the
Synthesis
Company
of California

© 2026

James E. Foley | doi.page

0 works0 citations0 h-index

James E. Foley

Publications by Year

Research Areas

Diabetes Treatment and Management, Metabolism, Diabetes, and Cancer, Pancreatic function and diabetes, Diabetes Management and Research, Peptidase Inhibition and Analysis

Most-Cited Works

→ Insulin Resistance and Insulin Secretory Dysfunction as Precursors of Non-Insulin-Dependent Diabetes Mellitus: Prospective Studies of Pima Indians(1993)1,508 cited
→ Enlarged subcutaneous abdominal adipocyte size, but not obesity itself, predicts Type II diabetes independent of insulin resistance(2000)788 cited
→ Vildagliptin, a Dipeptidyl Peptidase-IV Inhibitor, Improves Model-Assessed β-Cell Function in Patients with Type 2 Diabetes(2005)362 cited
→ A high concentration of fasting plasma non-esterified fatty acids is a risk factor for the development of NIDDM(1995)352 cited
→ Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes(2006)334 cited
→ Improved Meal-Related β-Cell Function and Insulin Sensitivity by the Dipeptidyl Peptidase-IV Inhibitor Vildagliptin in Metformin-Treated Patients With Type 2 Diabetes Over 1Year(2005)307 cited

→ Kinetics of glucose disposal in whole body and across the forearm in man.(1987)270 cited

→ Alpha cell function in health and disease: influence of glucagon-like peptide-1(2005)268 cited

→ In vitro insulin resistance of human adipocytes isolated from subjects with noninsulin-dependent diabetes mellitus.(1983)251 cited

→ Improved glycaemic control with dipeptidyl peptidase‐4 inhibition in patients with type 2 diabetes: vildagliptin (LAF237) dose response(2005)250 cited